Taken together, these results demonstrated that KTN1-AS1 was crucial for NSCLC tumor growth in vivo and the findings further indicated that KTN1-AS1 was able to potentially serve as a new therapeutic target in NSCLC treatment. Here, KTN1 is linked to neoplasm.